Patrick Burnett

771 total citations
43 papers, 321 citations indexed

About

Patrick Burnett is a scholar working on Dermatology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Patrick Burnett has authored 43 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Dermatology, 10 papers in Immunology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Patrick Burnett's work include Dermatology and Skin Diseases (11 papers), Psoriasis: Treatment and Pathogenesis (9 papers) and Autoimmune Bullous Skin Diseases (5 papers). Patrick Burnett is often cited by papers focused on Dermatology and Skin Diseases (11 papers), Psoriasis: Treatment and Pathogenesis (9 papers) and Autoimmune Bullous Skin Diseases (5 papers). Patrick Burnett collaborates with scholars based in United States, Canada and United Kingdom. Patrick Burnett's co-authors include Gerry Veenstra, Igor Puzanov, Keith T. Flaherty, David R. Berk, Robert Higham, Shenhong Wu, Hans Skvara, Christian Kollmannsberger, Nancy A. Dawson and Éric Raymond and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Investigative Dermatology and Fertility and Sterility.

In The Last Decade

Patrick Burnett

38 papers receiving 313 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick Burnett United States	10	68	66	65	56	44	43	321
Jessica S. Mounessa United States	8	65 1.0×	70 1.1×	26 0.4×	57 1.0×	22 0.5×	19	315
Shengbo Yang China	11	23 0.3×	57 0.9×	84 1.3×	93 1.7×	14 0.3×	22	309
Hsuan‐Hsiang Chen Taiwan	11	19 0.3×	63 1.0×	152 2.3×	89 1.6×	12 0.3×	25	423
Mary Coerver- Connolly Ireland	9	29 0.4×	97 1.5×	88 1.4×	9 0.2×	16 0.4×	17	420
Susan Holland United States	9	20 0.3×	180 2.7×	98 1.5×	109 1.9×	18 0.4×	18	402
Manveen Kaur Jawanda India	12	54 0.8×	21 0.3×	54 0.8×	65 1.2×	20 0.5×	29	537
Mary K. Tripp United States	10	22 0.3×	124 1.9×	45 0.7×	204 3.6×	11 0.3×	13	434
Anthony T. Williams United Kingdom	8	47 0.7×	90 1.4×	102 1.6×	13 0.2×	20 0.5×	12	445
Caroline Huber United States	9	37 0.5×	36 0.5×	102 1.6×	55 1.0×	11 0.3×	26	602
Hédi Khaı̈ri Tunisia	12	31 0.5×	112 1.7×	68 1.0×	11 0.2×	20 0.5×	56	676

Countries citing papers authored by Patrick Burnett

Since Specialization

Citations

This map shows the geographic impact of Patrick Burnett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Burnett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Burnett more than expected).

Fields of papers citing papers by Patrick Burnett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Burnett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Burnett. The network helps show where Patrick Burnett may publish in the future.

Co-authorship network of co-authors of Patrick Burnett

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Burnett. A scholar is included among the top collaborators of Patrick Burnett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Burnett. Patrick Burnett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Simpson, Eric L., Lawrence F. Eichenfield, Kim Papp, et al.. (2025). Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial. Dermatitis. 37(1). 75–83. 1 indexed citations

Eichenfield, Lawrence F., Vimal H. Prajapati, Joseph Browning, et al.. (2025). Efficacy and Safety of Once‐Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2–5 Years With Mild‐to‐Moderate Atopic Dermatitis ( INTEGUMENT ‐ PED ): A Phase 3 Randomized Controlled Trial. Pediatric Dermatology. 42(2). 296–304. 3 indexed citations

Ungar, Benjamin, Digpal Singh Gour, Joel Corrêa da Rosa, et al.. (2025). Tape-strip profiling identifies unique immune and lipid dysregulation in patients with seborrheic dermatitis. Journal of the American Academy of Dermatology. 92(6). 1277–1287. 5 indexed citations

Draelos, Zoé Kececioglu, et al.. (2024). Assessment of the Vehicle for Roflumilast Cream Compared to a Ceramide-Containing Moisturizing Cream in Mild Eczema. Journal of Drugs in Dermatology. 23(10). 834–840. 2 indexed citations

Bangert, Christine, Christian Loesche, Hans Skvara, et al.. (2023). IgE Depletion with Ligelizumab Does Not Significantly Improve Clinical Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis. Journal of Investigative Dermatology. 143(10). 1896–1905.e8. 10 indexed citations

Simpson, Eric L., Lawrence F. Eichenfield, Melinda Gooderham, et al.. (2023). 390 Efficacy and safety of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis in two phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2). British Journal of Dermatology. 188(Supplement_3). 1 indexed citations

Lebwohl, Mark, Linda Stein Gold, Melinda Gooderham, et al.. (2023). Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial. SKIN The Journal of Cutaneous Medicine. 7(2). s111–s111. 1 indexed citations

Lebwohl, Mark, Linda Stein Gold, Melinda Gooderham, et al.. (2023). CO45 Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults with Chronic Plaque Psoriasis from a 52-Week, Phase 2 Open-Label Safety Trial. Value in Health. 26(6). S22–S23. 1 indexed citations

Blauvelt, Andrew, Javier Alonso‐Llamazares, Neal Bhatia, et al.. (2023). Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial. SKIN The Journal of Cutaneous Medicine. 7(2). s196–s196.

10.

Simpson, Eric L., Lawrence F. Eichenfield, Melinda Gooderham, et al.. (2023). Efficacy and Safety of Roflumilast Cream 0.15% in Adults and Children Aged ≥6 Years With Mild to Moderate Atopic Dermatitis in Two Phase 3 Trials (INTEGUMENT-1 and INTEGUMENT-2). SKIN The Journal of Cutaneous Medicine. 7(4). s220–s220. 1 indexed citations

11.

Draelos, Zoe, David N. Adam, Hwanhee Hong, et al.. (2023). Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial. British Journal of Dermatology. 188(6). 810–812. 4 indexed citations

12.

Thurston, Archie, et al.. (2022). Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies. American Journal of Clinical Dermatology. 24(2). 315–324. 20 indexed citations

13.

Eichenfield, Lawrence F., Elaine C. Siegfried, Pearl Kwong, et al.. (2021). Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. American Journal of Clinical Dermatology. 22(2). 257–265. 9 indexed citations

14.

Guenthner, Scott, Pearl Kwong, Jayson Rieger, et al.. (2021). COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug–Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts. Dermatology and Therapy. 11(5). 1623–1634. 1 indexed citations

15.

Eichenfield, Lawrence F., et al.. (2021). Safety and Efficacy of VP-102 (Cantharidin, 0.7% w/v) in Molluscum Contagiosum by Body Region: Post hoc Pooled Analyses from Two Phase III Randomized Trials.. PubMed. 14(10). 42–47. 3 indexed citations

16.

Veenstra, Gerry & Patrick Burnett. (2014). Towards a relational health promotion. Health Promotion International. 31(1). dau068–dau068. 8 indexed citations

17.

Skvara, Hans, Patrick Burnett, Julie Jones, et al.. (2012). Quantification of skin lesions with a 3D stereovision camera system: validation and clinical applications. Skin Research and Technology. 19(1). e182–90. 19 indexed citations

18.

Puzanov, Igor, Patrick Burnett, & Keith T. Flaherty. (2011). Biological challenges of BRAF inhibitor therapy. Molecular Oncology. 5(2). 116–123. 27 indexed citations

19.

Puzanov, Igor, et al.. (2011). Evaluation of hand-foot syndrome (HFS) as a potential biomarker of sunitinib (SU) efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology. 29(15_suppl). e21113–e21113. 14 indexed citations

20.

Manji, Firoze & Patrick Burnett. (2005). African voices on development and social justice : editorials from Pambazuka news 2004. Medical Entomology and Zoology. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact